Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC healthcare AI clinical insights at $350M valuation Jul 2024 with 3M+ diagnoses surfaced and $50M+ incremental revenue for partners; $81.3M total ($61M Oak HC/FT Series B) serving Banner Health and Sentara competing with Nuance CDI.
Regard is a New York-based healthcare AI company — backed with $81.3 million in total funding including a $61 million Series B in July 2024 led by Oak HC/FT with Cedars-Sinai Health Ventures at a $350 million valuation, following a $15.3 million Series A in 2022 and $5 million seed in 2021 — providing health systems with an AI clinical insights platform that analyzes 100% of hospitalized patient medical record data to surface missed diagnoses to care teams, acting as an AI co-pilot for physicians that has surfaced 3 million+ diagnoses and generated $50+ million in incremental revenue for health system partners through improved documentation accuracy. Founded in 2019 by Eli Ben-Joseph, Nate Wilson, and Thomas Moulia (Stanford graduate students) and launched in 2021, Regard serves major health systems including Banner Health (33 acute care hospitals) and Sentara Health (12 hospitals).
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.